J. U. Gutterman

2.8k total citations
58 papers, 2.2k citations indexed

About

J. U. Gutterman is a scholar working on Oncology, Hematology and Immunology. According to data from OpenAlex, J. U. Gutterman has authored 58 papers receiving a total of 2.2k indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Oncology, 15 papers in Hematology and 15 papers in Immunology. Recurrent topics in J. U. Gutterman's work include Chronic Lymphocytic Leukemia Research (8 papers), Cancer Immunotherapy and Biomarkers (8 papers) and Chronic Myeloid Leukemia Treatments (8 papers). J. U. Gutterman is often cited by papers focused on Chronic Lymphocytic Leukemia Research (8 papers), Cancer Immunotherapy and Biomarkers (8 papers) and Chronic Myeloid Leukemia Treatments (8 papers). J. U. Gutterman collaborates with scholars based in United States, United Kingdom and Spain. J. U. Gutterman's co-authors include Moshe Talpaz, Gerald P. Bodey, Jorge R. Quesada, E. M. Hersh, Giora M. Mavligit, Emil J. Freireich, David A. Swanson, Patrick W. Trown, Adan Rios and Razelle Kurzrock and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Annals of Internal Medicine.

In The Last Decade

J. U. Gutterman

55 papers receiving 2.0k citations

Peers

Countries citing papers authored by J. U. Gutterman

Since Specialization

Citations

This map shows the geographic impact of J. U. Gutterman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J. U. Gutterman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J. U. Gutterman more than expected).

Fields of papers citing papers by J. U. Gutterman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J. U. Gutterman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J. U. Gutterman. The network helps show where J. U. Gutterman may publish in the future.

Co-authorship network of co-authors of J. U. Gutterman

This figure shows the co-authorship network connecting the top 25 collaborators of J. U. Gutterman. A scholar is included among the top collaborators of J. U. Gutterman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J. U. Gutterman. J. U. Gutterman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Pilot study of vitaxin?an angiogenesis inhibitor?in patients with advanced leiomyosarcomas 2001 ·Cancer ·(unknown), Jan Jenkins, Nicholas Papadopolous, M. A. Burgess, Carl Plager, J. U. Gutterman, (unknown)	74
2	INTERFERON Α2B AS ANTI-ANGIOGENESIS THERAPY OF GIANT CELL TUMOR OF BONE 1999 ·R. S. Benjamin, Shailen R. Patel, J. U. Gutterman	0
3	CHOP-Bleo plus interferon for stage IV low-grade lymphoma 1993 ·Annals of Oncology ·Peter McLaughlin, Fernando Cabanillas, Fredrick B. Hagemeister, F Swan, Jorge Romaguera, Sarah Taylor, Maria Alma Rodriguez, William S. Velasquez, J R Redman, J. U. Gutterman	46
4	Granulocyte‐macrophage colony‐stimulating factor as a cause of paraneoplastic leukaemoid reaction in advanced transitional cell carcinoma 1993 ·Journal of Internal Medicine ·Meir Wetzler, Zeev Estrov, Moshe Talpaz, Avi B. Markowitz, J. U. Gutterman, Razelle Kurzrock	35
5	Role of Granulocyte-Macrophage Colony-Stimulating Factor as Adjuvant Therapy for Fungal Infection in Patients with Cancer 1993 ·Clinical Infectious Diseases ·Gerald P. Bodey, E. Anaissie, J. U. Gutterman, Saroj Vadhan‐Raj	101
6	Very low doses of GM-CSF administered alone or with erythropoietin in a plastic anemia 1992 ·The American Journal of Medicine ·Razelle Kurzrock, Moshe Talpaz, J. U. Gutterman	23
7	α-Interferon Combination Therapy of Resistant Myeloma 1991 ·American Journal of Clinical Oncology ·Raymond Alexanian, Bart Barlogie, J. U. Gutterman	17
8	A phase I trial of recombinant alpha-2a Interferon (Roferon-A) with weekly cisplatinum 1991 ·Investigational New Drugs ·Kapil Dhingra, Moshe Talpaz, Hari M. Dhingra, (unknown), Jeanne M. Rothberg, J. U. Gutterman	13
9	Intensive chemotherapy induction followed by interferon-alpha maintenance in patients with Philadelphia chromosome-positive chronic myelogenous leukemia 1991 ·Cancer ·(unknown), Moshe Talpaz, Michael J. Keating, Elihu H. Estey, Susan O’Brien, Miloslav Beran, K. B. McCredie, J. U. Gutterman, Emil J. Freireich	34
10	Escalated Therapy for Refractory Urothelial Tumors: Methotrexate- Vinblastine-Doxorubicin- Cisplatin Plus Unglycosylated Recombinant Human Granulocyte-macrophage Colony-Stimulating Factor 1990 ·JNCI Journal of the National Cancer Institute ·Christopher J. Logothetis, F. H. Dexeus, Avishay Sella, R. J. Amato, Robert G. Kilbourn, Laury Finn, J. U. Gutterman	86
11	Effect of recombinant granulocyte/macrophage colony-stimulating factor on human monocyte activity in vitro and following intravenous administration. 1988 ·PubMed ·Eugenie S. Kleinerman, (unknown), Lawrence B. Lachman, J. U. Gutterman	37
12	Philadelphia-negative chronic myelogenous leukemia with breakpoint cluster region rearrangement: molecular analysis, clinical characteristics, and response to therapy. 1988 ·Journal of Clinical Oncology ·M Shtalrid, Moshe Talpaz, Mark Blick, (unknown), Hagop M. Kantarjian, K Taylor, (unknown), Jay Schachner, J. U. Gutterman, Razelle Kurzrock	38
13	Interferon-Induced Changes in Pharmacokinetics and Tumor Uptake of 111In-Labeled Antimelanoma Antibody 96.5 in Melanoma Patients 1988 ·JNCI Journal of the National Cancer Institute ·M. G. Rosenblum, L. Lamki, James L. Murray, Dennis J. Carlo, J. U. Gutterman	54
14	Molecular analysis of chromosome 22 breakpoints in adult Philadelphia-positive acute lymphoblastic leukaemia 1987 ·British Journal of Haematology ·Razelle Kurzrock, Mordechai Shtalrid, J. U. Gutterman, Charles Koller, Ronald S. Walters, José M. Trujillo, Moshe Talpaz	29
15	Therapy of chronic myelogenous leukemia 1987 ·Cancer ·Moshe Talpaz, Hagop M. Kantarjian, K. B. McCredie, José M. Trujillo, Michael J. Keating, J. U. Gutterman	21
16	Human leukocyte interferon (IFN) and mismatched, double-stranded RNA (dsRNA): synergistic antiproliferative activity in vitro 1985 ·Proceedings of the American Association for Cancer Research ·Michael G. Rosenblum, J. U. Gutterman	1
17	Human immune interferon and leukocyte interferon divert granulocyte macrophage colony forming and not to granulocytes 1984 ·Experimental Hematology ·D. S. Verma, Sundar Jagannath, J. U. Gutterman	2
18	Response of disseminated breast cancer to combined modality treatment with chemotherapy and levamisole with or without Bacillus Calmette-Guérin. 1978 ·PubMed ·G. N. Hortobagyi, H. Y. Yap, George R. Blumenschein, J. U. Gutterman, Aman U. Buzdar, Charles K. Tashima, E. M. Hersh	9
19	An effective new chemoimmunotherapy regimen for disseminated malignant melanoma (DMM) 1977 ·Proceedings of the American Association for Cancer Research ·J. U. Gutterman, E. M. Hersh, Robert S. Benjamin	9
20	Surface proteins of human acute myelogenous leukemia (AML) cells 1975 ·Federation Proceedings ·(unknown), E. M. Hersh, J. U. Gutterman	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact